PMID- 32150530
OWN - NLM
STAT- MEDLINE
DCOM- 20201130
LR  - 20201130
IS  - 1941-5923 (Electronic)
IS  - 1941-5923 (Linking)
VI  - 21
DP  - 2020 Mar 9
TI  - Composite Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Mantle Cell 
      Lymphoma; Small Cell Variant: A Real Diagnostic Challenge. Case Presentation and 
      Review of Literature.
PG  - e921131
LID - 10.12659/AJCR.921131 [doi]
AB  - BACKGROUND Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and 
      mantle cell lymphoma (MCL) both have a common origin arising from mature CD5+ 
      B-lymphocytes. Their distinction is crucial since MCL is a considerably more 
      aggressive disease. Composite lymphoma consisting of CLL/SLL and MCL has been 
      rarely reported. This type of composite lymphoma may be under-diagnosed as the 2 
      neoplasms have many features in common, both morphologically and 
      immunophenotypically. CASE REPORT We report the case of a 57-year-old male 
      patient who presented with a 4-month history of recurrent abdominal pain and 
      distention with hepatosplenomegaly. Peripheral blood showed a high leukocytes 
      count (46.7x10(3)/uL) with marked lymphocytosis of 35.0x10(3)/uL, mostly small 
      mature-looking, with some showing nuclear irregularities, with approximately 3% 
      prolymphocytes. Immunophenotyping by flow cytometry and immunohistochemistry 
      revealed 2 immunophenotypically distinct abnormal CD5+monotypic B-cell 
      populations. Fluorescence in situ hybridization (FISH) on peripheral blood 
      demonstrated IGH/CCND1 rearrangement consistent with t(11;14) in 65% of cells 
      analyzed. Accordingly, based on compilation of findings from morphology, flow 
      cytometry, immunohistochemistry, and FISH, A diagnosis of composite lymphoma 
      consisting of MCL; small cell variant and CLL/SLL was concluded. CONCLUSIONS We 
      describe a case of composite lymphoma of MCL (small cell variant) and CLL/SLL 
      that emphasizes the crucial role of the multiparametric approach, including 
      vigilant cyto-histopathologic examination, immunophenotyping by flow cytometry 
      and immunohistochemistry, as well as genetic testing, to achieve the correct 
      diagnosis.
FAU - Ibrahim, Feryal
AU  - Ibrahim F
AD  - Department of Laboratory Medicine and Pathology, National Center for Cancer Care 
      and Research (NCCCR), Hamad Medical Corporation, Doha, Qatar.
FAU - Al Sabbagh, Ahmad
AU  - Al Sabbagh A
AD  - Department of Laboratory Medicine and Pathology, National Center for Cancer Care 
      and Research (NCCCR), Hamad Medical Corporation, Doha, Qatar.
FAU - Amer, Aliaa
AU  - Amer A
AD  - Department of Laboratory Medicine and Pathology, Central Clinical Laboratory, 
      Hamad Medical Corporation, Doha, Qatar.
FAU - Soliman, Dina S
AU  - Soliman DS
AD  - Department of Laboratory Medicine and Pathology, National Center for Cancer Care 
      and Research (NCCCR), Hamad Medical Corporation, Doha, Qatar.
AD  - Department of Clinical Pathology, National Cancer Institute, Cairo University, 
      Cairo, Egypt.
FAU - Al Sabah, Hesham
AU  - Al Sabah H
AD  - Department of Hematology and Medical Oncology, National Center for Cancer Care 
      and Research (NCCCR), Hamad Medical Corporation, Doha, Qatar.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Review
DEP - 20200309
PL  - United States
TA  - Am J Case Rep
JT  - The American journal of case reports
JID - 101489566
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (IGH-CCND1 fusion protein, human)
RN  - 0 (Oncogene Proteins, Fusion)
SB  - IM
MH  - Biomarkers, Tumor
MH  - Composite Lymphoma/*diagnosis/*pathology
MH  - Diagnosis, Differential
MH  - Flow Cytometry
MH  - Gene Rearrangement
MH  - Humans
MH  - Immunohistochemistry
MH  - Immunophenotyping
MH  - In Situ Hybridization, Fluorescence
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/*diagnosis/*pathology
MH  - Lymphoma, Mantle-Cell/*diagnosis/*pathology
MH  - Male
MH  - Middle Aged
MH  - Oncogene Proteins, Fusion/genetics
PMC - PMC7083592
COIS- Conflict of interest: None declared Conflict of interest None.
EDAT- 2020/03/10 06:00
MHDA- 2020/12/01 06:00
PMCR- 2020/03/09
CRDT- 2020/03/10 06:00
PHST- 2020/03/10 06:00 [entrez]
PHST- 2020/03/10 06:00 [pubmed]
PHST- 2020/12/01 06:00 [medline]
PHST- 2020/03/09 00:00 [pmc-release]
AID - 921131 [pii]
AID - 10.12659/AJCR.921131 [doi]
PST - epublish
SO  - Am J Case Rep. 2020 Mar 9;21:e921131. doi: 10.12659/AJCR.921131.